...a WES-based analysis of paired CLL DNA samples isolated from 6 R/R CLL patients...confirmed the presence of the amp(1q23) as acquired at relapse after venetoclax in 3 out of 6 patients...venetoclax, a first-in-class BCL-2 inhibitor, leads to response in about 80% of patients with relapsed/refractory (R/R) CLL.